Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 458.76M | 482.04M | 433.14M | 450.89M | 468.06M | 338.30M |
Gross Profit | 343.58M | 366.30M | 326.66M | 345.87M | 353.86M | 250.98M |
EBITDA | -15.55M | 15.76M | 36.03M | 40.32M | 87.00M | 37.23M |
Net Income | -18.63M | 861.00K | 4.95M | 15.53M | 94.20M | 17.23M |
Balance Sheet | ||||||
Total Assets | 467.39M | 497.89M | 460.02M | 449.36M | 443.26M | 294.49M |
Cash, Cash Equivalents and Short-Term Investments | 109.97M | 135.57M | 104.34M | 102.48M | 113.93M | 84.39M |
Total Debt | 42.63M | 43.31M | 119.35M | 123.79M | 132.30M | 84.77M |
Total Liabilities | 99.33M | 112.57M | 181.36M | 183.69M | 201.22M | 148.41M |
Stockholders Equity | 242.90M | 385.32M | 278.66M | 265.67M | 242.03M | 146.08M |
Cash Flow | ||||||
Free Cash Flow | -7.00M | 4.18M | 6.55M | -9.04M | 30.76M | -14.34M |
Operating Cash Flow | 4.43M | 14.21M | 30.92M | 24.86M | 61.98M | 6.80M |
Investing Cash Flow | -11.44M | -10.03M | -24.36M | -33.90M | -31.22M | -24.83M |
Financing Cash Flow | 28.19M | 27.64M | -5.50M | -2.20M | -1.04M | 42.47M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
75 Outperform | $973.91M | 24.97 | 19.23% | ― | 17.17% | -51.97% | |
68 Neutral | $1.08B | 34.06 | 11.86% | 1.80% | 19.12% | 141.45% | |
63 Neutral | $853.63M | ― | -34.65% | ― | 252.64% | 85.10% | |
60 Neutral | $1.13B | ― | -37.23% | ― | 53.49% | 33.18% | |
56 Neutral | $479.51M | 928.57 | -4.92% | ― | 5.35% | -432.51% | |
51 Neutral | $7.55B | 0.30 | -61.90% | 2.27% | 17.11% | 1.58% | |
44 Neutral | $593.18M | ― | -949.46% | ― | 25.38% | 15.00% |
On June 23, 2025, Organogenesis Holdings held its Annual Meeting of Stockholders where several key proposals were voted on and approved. The meeting included the re-election of Garrett Lustig to the board of directors and the election of other directors to serve until the next annual meeting. Additionally, stockholders approved the compensation for named executive officers and the issuance of over 20% of Class A common stock upon conversion of Series A Convertible Preferred Stock, which may be deemed a change of control under Nasdaq rules. The appointment of RSM US LLP as the independent registered public accounting firm for 2025 was also ratified.
The most recent analyst rating on (ORGO) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Organogenesis Holdings stock, see the ORGO Stock Forecast page.